News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Receives registration of Valganciclovir powder for oral solution in Germany
Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Leading USA based genetic testing brand officially enters the Indian market
Subscribe To Our Newsletter & Stay Updated
